PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker.

Anna Csiszar, Stefano Tarantini, Andriy Yabluchanskiy, Zoltan Ungvari

Journal: GeroScience 2024;46(1):257-263

PMID: 38105401

Free Full Text on PubMed Central View on PubMed

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9), renowned for its pivotal role in low-density lipoprotein (LDL) regulation, has emerged as a compelling regulator of cardiometabolic aging. Beyond its well-established involvement in cholesterol metabolism, PCSK9's multifaceted influence on the aging processes of the cardiovascular and metabolic systems is garnering increasing attention. This review delves into the evolving landscape of PCSK9 in the context of cardiometabolic aging, offering fresh insights into its potential implications. Drawing inspiration from pioneering research conducted by the Pacher laboratory (Arif et al., Geroscience, 2023, PMID: 37726433), we delve into the intricate interplay of PCSK9 within the aging heart and liver, shedding light on its newfound significance. Recent studies underscore PCSK9's pivotal role in liver aging, suggesting intriguing connections between hepatic aging, lipid metabolism, and cardiovascular health. Additionally, we explore the therapeutic potential of PCSK9 as both a target and a biomarker, within the context of age-related cardiovascular disease.

Address: Vascular Cognitive Impairment, Neurodegeneration, and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.; Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.; OUHSC-SE International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary.; Vascular Cognitive Impairment, Neurodegeneration, and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. [email protected].; Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. [email protected].; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. [email protected].; OUHSC-SE International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary. [email protected].

DOI: 10.1007/s11357-023-01003-0

Link outs

Free resources

Full Text Sources:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3369

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/s11357-023-01003-0

MeSH Terms: Humans, Proprotein Convertase 9, Receptors, LDL, Biomarkers, Cardiovascular Diseases, Aging